Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?
Hurwitz
Barrie
B
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends; D006296:Health Services / Q000331:legislation & jurisprudence*; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008004:Licensure / Q000331:legislation & jurisprudence*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D016899:Interferon-beta; D000068556:Interferon beta-1a